MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Stock Quote (indian pharma)
- AUROBINDO PHARMA
AUROBINDO PHARMA Share Price (AUBD)
Here is the latest stock price and chart of Aurobindo Pharma. For more details, see the Aurobindo Pharma company fact sheet and quarterly results. For a sector overview, read our pharmaceuticals sector report.
Learn: How to Potentially Accumulate Rs 7 Crore in Wealth Over the Long-term
| Live BSE Quotes | May 14, 2021 11:52:00 AM | ||
|---|---|---|---|
| Price (Rs)1,004.10 | Open (Rs) 1,026.65 | High (Rs) 1,026.90 | Low (Rs) 1,002.70 |
| % Change-1.20 | Volume 37,604 | Value (Rs) 37,758,176 | 52-Week H/L 1,063.75 / 655.00 |
| Live NSE Quotes | May 14, 2021 11:54:58 AM | ||
|---|---|---|---|
| Price (Rs)1,003.10 | Open (Rs) 1,021.90 | High (Rs) 1,026.90 | Low (Rs) 1,002.10 |
| % Change-1.40 | Volume 1,115,153 | Value (Rs) 1,132,025,265 | 52-Week H/L 1,063.90 / 654.60 |
| Change | |||||
|---|---|---|---|---|---|
| 1 Day -1.20% | 1 Month 9.78% | 3 Months 7.71% | 1 Year 50.77% | 5 Years (CAGR)* 4.93% | 10 Years (CAGR)* 26.29% |
* Compound Annual Growth Rate
| Valuation | |||
|---|---|---|---|
| EPS (Rs)* 51.38 | P/E Ratio (x) 19.54 | Market Cap (Rs m) 587,568.19 | P/BV (x) 4.23 |
| *Trailing 12 months earnings, excluding extraordinary / exceptional items. | BSE Sensex | CNX Nifty |
- Charts
-
S&P BSE SENSEX 
PERIOD - Advanced Charts new
- Charts by TradingView
AUROBINDO PHARMA Share Price Today:
AUROBINDO PHARMA share price is down 1.2% to Rs 1,004.1 on the BSE. On the NSE, the AUROBINDO PHARMA share price is down 1.4% to Rs 1,003.1. The total volume of shares traded is 1.2 m.
Overall, the broader S&P BSE HEALTHCARE Index is trading down by 0.8%. And the benchmark S&P BSE SENSEX is at 48,604.8 (down 0.2%).
Over the last 30 days, the AUROBINDO PHARMA share price is up 9.6%. And over the last one year, AUROBINDO PHARMA share price is up 51.2%.
What else is happening in the markets today? Dig in...
- TRACK NOW:
- Most Active Stocks Rs 0 to 10
- Most Active Stocks Rs 10 to 20
- Top Gainers Today BSE A Group
- Top Gainers Today NSE Above Rs 20
- Top Gainers Today BSE Above Rs 20
- Top Gainers Today BSE Sensex
- Top Gainers Today BSE Small Cap
- Top Gainers Today BSE 500
- Top Losers Today BSE A Group
- Most Active Stocks Rs 1 to 2
- Top Losers Today NSE Above Rs 20
- Buzzing Stocks Today
- Most Popular Stocks BSE 30
- TRENDING ON EQUITYMASTER:
- Warren Buffett - The Value Investor
- Your Ultimate Guide to Penny Stock Investing
- How to Invest in Gold
- Basics of Value Investing
- Benjamin Graham
- The Best Bluechip Stocks to Buy
- How to Invest in Silver
- The Best Small-cap Stocks to Buy
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Best Stocks to Buy Today
- How to Use P/E for Successful Investing
- How to Find Undervalued Stocks
- Differences Between Trading and Investing
- SWOT Analysis for Stocks
- The Best Dividend Stocks to Buy
Today's Market
Sensex Opens Flat; Asian Paints Rallies 7% Post Q4 Results(09:30 am)
Asian stock markets climbed today after US benchmarks halted a three-day slide, with signs of a strengthening labor market outweighing investors' concerns about rising inflation.
Related Views On News
AUROBINDO PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 25.6% (Quarterly Result Update)
Sep 15, 2020 | Updated on Sep 15, 2020For the quarter ended June 2020, AUROBINDO PHARMA has posted a net profit of Rs 8 bn (up 25.6% YoY). Sales on the other hand came in at Rs 59 bn (up 8.8% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
AUROBINDO PHARMA Announces Quarterly Results (4QFY20); Net Profit Up 48.2% (Quarterly Result Update)
Jun 5, 2020 | Updated on Jun 5, 2020For the quarter ended March 2020, AUROBINDO PHARMA has posted a net profit of Rs 9 bn (up 48.2% YoY). Sales on the other hand came in at Rs 62 bn (up 16.4% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.
What's Behind the Rally in Pharma Stocks? (Views On News)
May 11, 2021The second wave of Covid has given a new lease of life to pharma stocks.
Why Did Alembic Pharma Shares Fall Today? (Views On News)
May 5, 2021Covid-led supply disruptions of API fuel Alembic Pharma's global prospects.
AUROBINDO PHARMA 2018-19 Annual Report Analysis (Annual Result Update)
Nov 6, 2019 | Updated on Nov 6, 2019Here's an analysis of the annual report of AUROBINDO PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of AUROBINDO PHARMA. Also includes updates on the valuation of AUROBINDO PHARMA.
More Views on NewsMost Popular
Are the Stock Markets Deaf to Covid Agony? (Profit Hunter)
May 6, 2021Why are markets discounting the economic impact of Covid?
My Secret to Find Breakthrough Stocks (Fast Profits Daily)
May 7, 2021I've used this trading technique for many years with great success. I'm sharing it with you today.
The Worst Sector in the Market (Fast Profits Daily)
May 11, 2021The worst sector in the stock market according to the charts.
The Key to Profit from India's EV Revolution (Profit Hunter)
May 7, 2021Stocks you must consider investing in before buying your first electric vehicle.
MoreOUR TOP 5 IDEAS
- FREE Event: Discover Your First Stock for a Potential Rs 7 Crore in Long-term Wealth
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK AUROBINDO PHARMA
- Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON AUROBINDO PHARMA
AUROBINDO PHARMA - ADCOCK INGRAM COMPARISON
COMPARE AUROBINDO PHARMA WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
- Momentum Moves
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.